Effect of Liraglutide on Vascular Inflammation Evaluated by [<sup>64</sup>Cu]DOTATATE

Effect of Liraglutide on Vascular Inflammation Evaluated by [<sup>64</sup>Cu]DOTATATE

Quantification of vascular inflammation before and after treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may help reveal mechanistic pathways underlying the cardiovascular benefits of these drugs. We assessed change in vascular inflammation in the carotid arteries over 26 weeks...

Full description

Bibliographic Details
Main Authors:	Emilie H. Zobel, Rasmus S. Ripa, Bernt J. von Scholten, Viktor Rotbain Curovic, Lars Jorge Diaz, Tine W. Hansen, Peter Rossing, Andreas Kjaer
Format:	Article
Language:	English
Published:	MDPI AG 2021-08-01
Series:	Diagnostics
Subjects:	GLP-1 RA vascular inflammation PET type 2 diabetes
Online Access:	https://www.mdpi.com/2075-4418/11/8/1431

Similar Items

Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial
by: Jacob K. Jensen, et al.
Published: (2021-11-01)

Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial
by: Asger Wretlind, et al.
Published: (2022-03-01)

Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial
by: Andreas Kjær, et al.
Published: (2021-10-01)

Initial Experience with <sup>64</sup>Cu-DOTATATE Digital PET of Patients with Neuroendocrine Neoplasms: Comparison with Analog PET
by: Mathias Loft, et al.
Published: (2021-02-01)

<sup>64</sup>Cu-DOTATATE Positron Emission Tomography (PET) of <i>Borrelia Burgdorferi</i> Infection: In Vivo Imaging of Macrophages in Experimental Model of Lyme Arthritis
by: Anne Skovsbo Clausen, et al.
Published: (2020-10-01)

Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials
by: Asger Wretlind, et al.
Published: (2023-09-01)

Peptide Receptor Radionuclide Therapy Using <sup>90</sup>Y- and <sup>177</sup>Lu-DOTATATE Modulating Atherosclerotic Plaque Inflammation: Longitudinal Monitoring by <sup>68</sup>Ga-DOTATATE Positron Emissions Tomography/Computer Tomography
by: German Rubinstein, et al.
Published: (2024-11-01)

[<sup>68</sup>Ga]Ga-NODAGA-E[(cRGDyK)]<sub>2</sub> and [<sup>64</sup>Cu]Cu-DOTATATE PET Predict Improvement in Ischemic Cardiomyopathy
by: Bjarke Follin, et al.
Published: (2023-01-01)

Semiquantitative Analysis of Physiological Biodistribution of <sup>68</sup>Ga-DOTATATE and <sup>68</sup>Ga-DOTANOC
by: Evrim SÜRER BUDAK, et al.
Published: (2023-07-01)

<sup>68</sup>Ga-DOTATATE and <sup>68</sup>Ga-Pentixafor PET/CT in a Patient with Castleman Disease of the Retroperitoneum
by: Rui Zuo, et al.
Published: (2024-02-01)

NHS-Functionalized THP Derivative for Efficient Synthesis of Kit-Based Precursors for <sup>68</sup>Ga Labeled PET Probes
by: Giuseppe Floresta, et al.
Published: (2021-04-01)

Out of stock: A brief clinical reference for rough equivalency of glucagon‐like peptide‐1 (GLP‐1) ± glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes
by: Leigh Perreault, et al.
Published: (2024-06-01)

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
by: Teshome G, et al.
Published: (2020-09-01)

Brain Imaging of the GLP-1 Receptor in Obesity Using <sup>68</sup>Ga-NODAGA-Exendin-4 PET
by: Laura N. Deden, et al.
Published: (2021-12-01)

Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study
by: Jasmine Melissa Madsen, et al.
Published: (2025-01-01)

The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls
by: Jens Christian Laursen, et al.
Published: (2021-12-01)

FDG-PET/CT-based respiration-gated lung segmentation and quantification of lung inflammation in COPD patients
by: Ayse Dudu Altintas Dogan, et al.
Published: (2024-06-01)

Impact of [<sup>18</sup>F]FDG-PET and [<sup>18</sup>F]FLT-PET-Parameters in Patients with Suspected Relapse of Irradiated Lung Cancer
by: Tine N. Christensen, et al.
Published: (2021-02-01)

Hepatic function of glucagon-like peptide-1 and its based diabetes drugs
by: Feng Jia Nuo, et al.
Published: (2024-08-01)

Evaluation of [<sup>64</sup>Cu]Cu-NOTA-PEG<sub>7</sub>-H-Tz for Pretargeted Imaging in LS174T Xenografts—Comparison to [<sup>111</sup>In]In-DOTA-PEG<sub>11</sub>-BisPy-Tz
by: Christian B. M. Poulie, et al.
Published: (2021-01-01)

Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction
by: Qianyi Li, et al.
Published: (2024-07-01)

Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
by: Joanne Thanh-Tâm Nguyen, et al.
Published: (2024-09-01)

Efficacy and safety of liraglutide in Indian adolescents with obesity
by: I. S. Kochar, et al.
Published: (2019-06-01)

Preparation and Evaluation of <sup>64</sup>Cu-Radiolabled Dual-Ligand Multifunctional Gold Nanoparticles for Tumor Theragnosis
by: Karim Mhanna, et al.
Published: (2023-01-01)

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
by: Qiyuan Keith Liu
Published: (2024-07-01)

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
by: Ana Petrovic, et al.
Published: (2023-05-01)

Non-[<sup>18</sup>F]FDG PET-Radiopharmaceuticals in Oncology
by: Antonia Dimitrakopoulou-Strauss, et al.
Published: (2024-12-01)

<sup>64</sup>Cu-ATSM and <sup>18</sup>FDG PET uptake and <sup>64</sup>Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry
by: Hansen Anders E, et al.
Published: (2012-06-01)

Long-Term Survival and Value of <sup>18</sup>F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with <sup>177</sup>Lu-DOTATATE
by: Margarida Rodrigues, et al.
Published: (2021-03-01)

Potential of GLP-1 Analogs in Managing Hyperphagia and Obesity in Prader-Willi Syndrome: A Review of Efficacy and Safety
by: Olga Grelewicz, et al.
Published: (2024-10-01)

Lutathera<sup>®</sup> Orphans: State of the Art and Future Application of Radioligand Therapy with <sup>177</sup>Lu-DOTATATE
by: Luca Urso, et al.
Published: (2023-03-01)

Role of Combined <sup>68</sup>Ga DOTA-Peptides and <sup>18</sup>F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
by: Chalermrat Kaewput, et al.
Published: (2022-01-01)

Evaluation of a <sup>68</sup>Ga-Labeled DOTA-Tetrazine as a PET Alternative to <sup>111</sup>In-SPECT Pretargeted Imaging
by: Patricia E. Edem, et al.
Published: (2020-01-01)

Continuation of Liraglutide during Fasting is not Associated with Hypoglycaemia
by: Rosalie Koot, et al.
Published: (2017-10-01)

Clinical Impact of Liraglutide as a Treatment of Obesity
by: Alruwaili H, et al.
Published: (2021-03-01)

Preclinical Evaluation of a <sup>64</sup>Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma
by: Cassandra Métivier, et al.
Published: (2023-06-01)

The Discovery and Development of Liraglutide and Semaglutide
by: Lotte Bjerre Knudsen, et al.
Published: (2019-04-01)

A convolutional neural network for total tumor segmentation in [64Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms
by: Esben Andreas Carlsen, et al.
Published: (2022-05-01)

ACUTE PANCREATITIS ASSOCIATED WITH EXENATIDE AND LIRAGLUTIDE: A META-ANALYSIS
by: Carlos Alves, et al.
Published: (2012-09-01)

Acute Pancreatitis Associated with Exenatide and Liraglutide: a Meta-Analysis
by: Carlos Alves, et al.
Published: (2012-07-01)